Zacks Research Brokers Lift Earnings Estimates for Revvity

Revvity Inc. (NYSE:RVTY) – Equities research analysts at Zacks Research increased their Q2 2026 earnings estimates for Revvity in a research report issued on Monday, February 23rd. Zacks Research analyst Team now anticipates that the company will post earnings of $1.31 per share for the quarter, up from their prior forecast of $1.29. The consensus estimate for Revvity’s current full-year earnings is $4.94 per share. Zacks Research also issued estimates for Revvity’s Q3 2026 earnings at $1.34 EPS, FY2026 earnings at $5.36 EPS and Q1 2027 earnings at $1.28 EPS.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Monday, February 2nd. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The firm had revenue of $772.06 million during the quarter, compared to analyst estimates of $759.81 million. During the same quarter last year, the business posted $1.42 EPS. The company’s revenue was up 5.9% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS.

RVTY has been the topic of several other reports. Robert W. Baird set a $129.00 price target on Revvity in a research report on Tuesday, February 3rd. The Goldman Sachs Group began coverage on Revvity in a report on Tuesday, December 9th. They issued a “neutral” rating and a $105.00 target price on the stock. TD Cowen restated a “hold” rating on shares of Revvity in a report on Tuesday, February 3rd. Bank of America lowered shares of Revvity from a “buy” rating to a “neutral” rating and set a $110.00 price objective on the stock. in a research note on Monday, December 15th. Finally, Barclays lifted their target price on shares of Revvity from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Tuesday, February 3rd. Five analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $113.67.

Revvity Price Performance

RVTY opened at $97.63 on Thursday. The firm has a market capitalization of $11.07 billion, a P/E ratio of 46.94, a PEG ratio of 2.07 and a beta of 1.07. The stock has a fifty day moving average of $103.21 and a 200-day moving average of $96.30. The company has a quick ratio of 1.40, a current ratio of 1.68 and a debt-to-equity ratio of 0.36. Revvity has a 12-month low of $81.36 and a 12-month high of $120.39.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 8th. Stockholders of record on Friday, April 17th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Friday, April 17th. Revvity’s dividend payout ratio (DPR) is currently 13.46%.

Institutional Investors Weigh In On Revvity

Several hedge funds have recently modified their holdings of the business. Byrne Asset Management LLC grew its position in Revvity by 0.9% in the 4th quarter. Byrne Asset Management LLC now owns 11,138 shares of the company’s stock worth $1,078,000 after purchasing an additional 100 shares during the last quarter. New Mexico Educational Retirement Board boosted its stake in Revvity by 1.9% in the 4th quarter. New Mexico Educational Retirement Board now owns 5,416 shares of the company’s stock valued at $524,000 after buying an additional 100 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Revvity by 8.9% in the 4th quarter. Allworth Financial LP now owns 1,275 shares of the company’s stock worth $123,000 after purchasing an additional 104 shares during the last quarter. Trust Point Inc. grew its stake in Revvity by 3.8% during the fourth quarter. Trust Point Inc. now owns 3,215 shares of the company’s stock worth $311,000 after buying an additional 117 shares during the last quarter. Finally, First National Advisers LLC grew its position in Revvity by 0.8% during the 3rd quarter. First National Advisers LLC now owns 15,023 shares of the company’s stock worth $1,317,000 after acquiring an additional 125 shares during the last quarter. 86.65% of the stock is owned by institutional investors.

Revvity News Summary

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q4 beat and upbeat 2026 outlook underpin investor sentiment — coverage pieces note Revvity’s better‑than‑expected Q4 results and management’s favorable FY‑2026 guidance, which helps justify the stock’s premium relative to near‑term estimates. How Investors May Respond To Revvity (RVTY) Strong Q4 Beat And Upbeat 2026 Outlook
• Positive Sentiment: Zacks raised its Q4 2026 estimate (to $1.69 from $1.58) — a lift to that quarter’s outlook that partially offsets other cuts and signals some confidence in Revvity’s late‑2026 trajectory. (Zacks Research note)
• Neutral Sentiment: Analyst sentiment overview stories are circulating assessing how Wall Street views Revvity’s prospects — these articles summarize buy/hold/sell distribution but don’t report major new analyst actions. Do Wall Street analysts like Revvity stock?
• Neutral Sentiment: Comparative coverage (Progyny vs. Revvity) offers cross‑sector context for investors considering relative exposure but doesn’t materially change Revvity’s fundamentals. Financial Comparison: Progyny (NASDAQ:PGNY) vs. Revvity (NYSE:RVTY)
• Negative Sentiment: Zacks trimmed several near‑term EPS estimates (Q1‑2026: from $1.11 to $1.03; Q2‑2027: 1.51→1.48; Q3‑2027: 1.48→1.45; Q4‑2027: 1.72→1.69) and lowered FY‑2027 to $5.90 from $5.97 — these cuts are modest but signal slightly reduced growth expectations and could pressure sentiment if other shops follow. (Zacks Research notes)

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.